View in EDS HTML Full Text PDF Full Text

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.

Saved in:
Bibliographic Details
Title: A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
Authors: Gupta N; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA. Neeraj.Gupta@takeda.com., Zhang S; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA., Pusalkar S; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA., Plesescu M; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA., Chowdhury S; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA., Hanley MJ; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA., Wang B; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA., Xia C; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA., Zhang X; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA., Venkatakrishnan K; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA., Shepard DR; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Source: Investigational new drugs [Invest New Drugs] 2018 Jun; Vol. 36 (3), pp. 407-415. Date of Electronic Publication: 2017 Sep 21.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 28932928
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase I study to assess the mass balance, excretion, and pharmacokinetics of [<superscript>14</superscript>C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gupta+N%22">Gupta N</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA. Neeraj.Gupta@takeda.com.<br /><searchLink fieldCode="AU" term="%22Zhang+S%22">Zhang S</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.<br /><searchLink fieldCode="AU" term="%22Pusalkar+S%22">Pusalkar S</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.<br /><searchLink fieldCode="AU" term="%22Plesescu+M%22">Plesescu M</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.<br /><searchLink fieldCode="AU" term="%22Chowdhury+S%22">Chowdhury S</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.<br /><searchLink fieldCode="AU" term="%22Hanley+MJ%22">Hanley MJ</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.<br /><searchLink fieldCode="AU" term="%22Wang+B%22">Wang B</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.<br /><searchLink fieldCode="AU" term="%22Xia+C%22">Xia C</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+X%22">Zhang X</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.<br /><searchLink fieldCode="AU" term="%22Venkatakrishnan+K%22">Venkatakrishnan K</searchLink>; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA, 02139, USA.<br /><searchLink fieldCode="AU" term="%22Shepard+DR%22">Shepard DR</searchLink>; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2018 Jun; Vol. 36 (3), pp. 407-415. <i>Date of Electronic Publication: </i>2017 Sep 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28932928
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-017-0509-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 407
    Titles:
      – TitleFull: A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gupta N
      – PersonEntity:
          Name:
            NameFull: Zhang S
      – PersonEntity:
          Name:
            NameFull: Pusalkar S
      – PersonEntity:
          Name:
            NameFull: Plesescu M
      – PersonEntity:
          Name:
            NameFull: Chowdhury S
      – PersonEntity:
          Name:
            NameFull: Hanley MJ
      – PersonEntity:
          Name:
            NameFull: Wang B
      – PersonEntity:
          Name:
            NameFull: Xia C
      – PersonEntity:
          Name:
            NameFull: Zhang X
      – PersonEntity:
          Name:
            NameFull: Venkatakrishnan K
      – PersonEntity:
          Name:
            NameFull: Shepard DR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2018 Jun
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Numbering:
            – Type: volume
              Value: 36
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1